Short-Term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference: A Pilot Study of Obese Japanese Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: To examine the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on visceral fat adiposity, appetite, food preference, and biomarkers of cardiovascular system in Japanese patients with type 2 diabetes. METHODS: The study subjects were 20 inpatients with type 2 diabetes treated with liraglutide [age; 61.2 ± 14.0 years, duration of diabetes; 16.9 ± 6.6 years, glycated hemoglobin (HbA1c); 9.1 ± 1.2%, body mass index (BMI); 28.3 ± 5.2 kg/m(2), mean ± SD]. After improvement in glycemic control by insulin or oral glucose-lowering agents, patients were switched to liraglutide. We assessed the estimated visceral fat area (eVFA) by abdominal bioelectrical impedance analysis, glycemic control by the 75-g oral glucose tolerance test (OGTT) and eating behavior by the Japan Society for the Study of Obesity questionnaire. RESULTS: Treatment with liraglutide (dose range: 0.3 to 0.9 mg/day) for 20.0 ± 6.4 days significantly reduced waist circumference, waist/hip ratio, eVFA. It also significantly improved the scores of eating behavior, food preference and the urge for fat intake and tended to reduce scores for sense of hunger. Liraglutide increased serum C-peptide immunoreactivity and disposition index. CONCLUSIONS: Short-term treatment with liraglutide improved visceral fat adiposity, appetite, food preference and the urge for fat intake in obese Japanese patients with type 2 diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 receptor agonists decrease energy intake and reduce adipose tissue.
“GLP-1RAs decrease energy intake and provide adipose tissue reduction [114].”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 89
- Authors
- Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I.
- Affiliations
- The University of Osaka (JP)
- Corresponding author
- Maeda, Norikazu
- Venue
- Cardiovascular Diabetology
- Published
- 2011-12
- Volume
- 10
- Issue
- 1
- Pages
- 109-109
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC3260096
- OpenAlex
- W2153705693
- Cited by
- 89
- References
- 39
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 11 · 2017: 6 · 2016: 6 · 2015: 10 · 2014: 11 · 2013: 8 · 2012: 4
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (21591184, 22590979)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- liraglutide, GLP-1 receptor agonists, type 2 diabetes, visceral fat, obesity, appetite, food preferences, dietary habits, waist circumference, C-peptide, insulin sensitivity, Japanese patients
- MeSH terms
- Liraglutide, Aged, Appetite, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Food Preferences, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Japan, Male, Middle Aged, Obesity, Pilot Projects, Surveys and Questionnaires, Time Factors, Biomarkers, Body Mass Index, Treatment Outcome, Electric Impedance, Intra-Abdominal Fat, Adiposity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
